Oruka Therapeutics, Inc. (ORKA)
Nasdaq: ORKA · Pharmaceutical Preparations · Menlo Park, CA · filing with the SEC since 1997
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Mar 12, 2026 | Mar 6, 2025 | Feb 1, 2024 | Feb 24, 2023 | Mar 14, 2022 | Mar 18, 2021 | Feb 18, 2020 | Feb 27, 2019 | Mar 22, 2018 | Mar 21, 2017 |
| Revenue | · | · | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 100,640 | · | 1,013 | 4,749 | 13,832 | 4,992 | 1,833 | 4,239 | 14,076 | 12,348 |
| General and administrative | 21,411 | · | 6,283 | 5,847 | 5,503 | 4,774 | 3,981 | 3,879 | 4,636 | 4,265 |
| Total operating expenses | 122,051 | · | 7,296 | 10,596 | 19,335 | 9,766 | 5,814 | 8,118 | 18,712 | 16,613 |
| Operating income | -122,051 | · | -7,296 | -10,596 | -19,335 | -9,766 | -5,814 | -8,118 | -18,712 | -16,613 |
| Interest expense | · | · | · | · | · | 9 | 7 | 8 | 6 | · |
| Interest and investment income | 16,630 | · | · | · | · | · | · | · | · | · |
| Other income (expense), net | -12 | · | · | · | · | · | · | · | · | · |
| Total non-operating income (expense) | 16,618 | · | · | · | · | · | · | · | · | · |
| Income before income taxes | -105,433 | · | · | · | -19,322 | -9,747 | -5,649 | -7,964 | -18,551 | -16,444 |
| Income tax expense | · | · | 0 | 0 | 0 | -9 | -167 | -31 | -61 | 0 |
| Net income | -105,433 | · | -5,339 | -9,926 | -19,322 | -9,738 | -5,482 | -7,933 | -18,490 | -16,444 |
| Earnings per share, basic | · | · | -0.37 | -0.69 | -1.39 | · | · | · | · | · |
| Earnings per share, diluted | · | · | -0.37 | -0.69 | -1.39 | · | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -1.39 | -2.07 | -4.15 | -10.31r | -1.77 | -1.81 |
| Weighted average shares, basic | · | · | 14,415,877 | 14,410,143 | 13,903,871 | · | · | · | · | · |
| Weighted average shares, diluted | · | · | 14,415,877 | 14,410,143 | 13,903,871 | · | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 13,903,871 | 4,710,237 | 1,321,234 | 769,392r | 10,431,391 | 9,067,438 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted